Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE).

MLA

Simon, Jakub K., et al. “Lot-to-Lot Consistency, Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Healthy Adults Aged ≥50 Years: A Randomized Phase 3 Trial (PNEU-TRUE).” Vaccine, vol. 40, no. 9, Feb. 2022, pp. 1342–51. EBSCOhost, https://doi.org/10.1016/j.vaccine.2021.12.067.

APA

Simon, J. K., Staerke, N. B., Hemming-Harlo, M., Layle, S., Dagan, R., Shekar, T., Pedley, A., Jumes, P., Tamms, G., Sterling, T., Musey, L., & Buchwald, U. K. (2022). Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged ≥50 years: A randomized phase 3 trial (PNEU-TRUE). Vaccine, 40(9), 1342–1351. https://doi.org/10.1016/j.vaccine.2021.12.067

Chicago

Simon, Jakub K, Nina Breinholt Staerke, Maria Hemming-Harlo, Stacey Layle, Ron Dagan, Tulin Shekar, Alison Pedley, et al. 2022. “Lot-to-Lot Consistency, Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Healthy Adults Aged ≥50 Years: A Randomized Phase 3 Trial (PNEU-TRUE).” Vaccine 40 (9): 1342–51. doi:10.1016/j.vaccine.2021.12.067.